TY - JOUR AU - Strumberg, D. AU - Schultheis, B. AU - Adamietz, I. A. PY - 2008 DA - 2008// TI - Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours JO - Br J Cancer VL - 99 UR - https://doi.org/10.1038/sj.bjc.6604724 DO - 10.1038/sj.bjc.6604724 ID - Strumberg2008 ER - TY - JOUR AU - Escudier, B. AU - Eisen, T. AU - Stadler, W. M. PY - 2007 DA - 2007// TI - Sorafenib in advanced clear-cell renal-cell carcinoma JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa060655 DO - 10.1056/NEJMoa060655 ID - Escudier2007 ER - TY - JOUR AU - Escudier, B. AU - Eisen, T. AU - Stadler, W. M. PY - 2007 DA - 2007// TI - Sorafenib in advanced clear-cell renal-cell carcinoma JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa060655 DO - 10.1056/NEJMoa060655 ID - Escudier2007 ER - TY - JOUR AU - Saltz, L. B. AU - Rosen, L. S. AU - Marshall, J. L. PY - 2007 DA - 2007// TI - Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2007.12.8637 DO - 10.1200/JCO.2007.12.8637 ID - Saltz2007 ER - TY - CHAP AU - Mross, K. PY - 2007 DA - 2007// BT - Angiogeneseinhibition in der Onkologie PB - UNI-MED Science CY - Bremen - London - Boston ID - Mross2007 ER -